TY - JOUR
T1 - Machine learning evaluation of intensified conditioning on haematopoietic stem cell transplantation in adult acute lymphoblastic leukemia patients
AU - Jo, Tomoyasu
AU - Inoue, Kosuke
AU - Ueda, Tomoaki
AU - Iwasaki, Makoto
AU - Akahoshi, Yu
AU - Nishiwaki, Satoshi
AU - Hatsusawa, Hiroki
AU - Nishida, Tetsuya
AU - Uchida, Naoyuki
AU - Ito, Ayumu
AU - Tanaka, Masatsugu
AU - Takada, Satoru
AU - Kawakita, Toshiro
AU - Ota, Shuichi
AU - Katayama, Yuta
AU - Takahashi, Satoshi
AU - Onizuka, Makoto
AU - Hasegawa, Yuta
AU - Kataoka, Keisuke
AU - Kanda, Yoshinobu
AU - Fukuda, Takahiro
AU - Tabuchi, Ken
AU - Atsuta, Yoshiko
AU - Arai, Yasuyuki
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Background: The advantage of intensified myeloablative conditioning (MAC) over standard MAC has not been determined in haematopoietic stem cell transplantation (HSCT) for adult acute lymphoblastic leukemia (ALL) patients. Methods: To evaluate heterogeneous effects of intensified MAC among individuals, we analyzed the registry database of adult ALL patients between 2000 and 2021. After propensity score matching, we applied a machine-learning Bayesian causal forest algorithm to develop a prediction model of individualized treatment effect (ITE) of intensified MAC on reduction in overall mortality at 1 year after HSCT. Results: Among 2440 propensity score-matched patients, our model shows heterogeneity in the association between intensified MAC and 1-year overall mortality. Individuals in the high-benefit group (n = 1220), defined as those with ITEs greater than the median, are more likely to be younger, male, and to have higher refined Disease Risk Index (rDRI), T-cell phenotype, and grafts from related donors than those in the low-benefit group (n = 1220). The high-benefit approach (applying intensified MAC to individuals in the high-benefit group) shows the largest reduction in overall mortality at 1 year (risk difference [95% confidence interval], +5.94 percentage points [0.88 to 10.51], p = 0.011). In contrast, the high-risk approach (targeting patients with high or very high rDRI) does not achieve statistical significance (risk difference [95% confidence interval], +3.85 percentage points [−1.11 to 7.90], p = 0.063). Conclusions: These findings suggest that the high-benefit approach, targeting patients expected to benefit from intensified MAC, has the capacity to maximize HSCT effectiveness using intensified MAC.
AB - Background: The advantage of intensified myeloablative conditioning (MAC) over standard MAC has not been determined in haematopoietic stem cell transplantation (HSCT) for adult acute lymphoblastic leukemia (ALL) patients. Methods: To evaluate heterogeneous effects of intensified MAC among individuals, we analyzed the registry database of adult ALL patients between 2000 and 2021. After propensity score matching, we applied a machine-learning Bayesian causal forest algorithm to develop a prediction model of individualized treatment effect (ITE) of intensified MAC on reduction in overall mortality at 1 year after HSCT. Results: Among 2440 propensity score-matched patients, our model shows heterogeneity in the association between intensified MAC and 1-year overall mortality. Individuals in the high-benefit group (n = 1220), defined as those with ITEs greater than the median, are more likely to be younger, male, and to have higher refined Disease Risk Index (rDRI), T-cell phenotype, and grafts from related donors than those in the low-benefit group (n = 1220). The high-benefit approach (applying intensified MAC to individuals in the high-benefit group) shows the largest reduction in overall mortality at 1 year (risk difference [95% confidence interval], +5.94 percentage points [0.88 to 10.51], p = 0.011). In contrast, the high-risk approach (targeting patients with high or very high rDRI) does not achieve statistical significance (risk difference [95% confidence interval], +3.85 percentage points [−1.11 to 7.90], p = 0.063). Conclusions: These findings suggest that the high-benefit approach, targeting patients expected to benefit from intensified MAC, has the capacity to maximize HSCT effectiveness using intensified MAC.
UR - https://www.scopus.com/pages/publications/85210181102
UR - https://www.scopus.com/pages/publications/85210181102#tab=citedBy
U2 - 10.1038/s43856-024-00680-y
DO - 10.1038/s43856-024-00680-y
M3 - Article
AN - SCOPUS:85210181102
SN - 2730-664X
VL - 4
JO - Communications Medicine
JF - Communications Medicine
IS - 1
M1 - 247
ER -